The Lancet Rheumatology, 2(12), e764-e773. Lancet Publishing Group The Lancet Rheumatology, 2(12), E764-E773. Lancet Publishing Group Vlaar, A P J, de Bruin, S, Busch, M, Timmermans, S A M E G, van Zeggeren, I E, Koning, R, Ter Horst, L, Bulle, E B, van Baarle, F E H P, van de Poll, M C G, Kemper, E M, van der Horst, I C C, Schultz, M J, Horn, J, Paulus, F, Bos, L D, Wiersinga, W J, Witzenrath, M, Rueckinger, S, Pilz, K, Brouwer, M C, Guo, R-F, Heunks, L, van Paassen, P, Riedemann, N C & van de Beek, D 2020, ' Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO) : an exploratory, open-label, phase 2 randomised controlled trial ', The Lancet Rheumatology, vol. 2, no. 12, pp. e764-e773 . https://doi.org/10.1016/S2665-9913(20)30341-6 The Lancet Rheumatology